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Background: Traditional diagnoses of major depressive disorder (MDD) suggested that the presence or absence of
stress prior to onset results in either ‘reactive’ or ‘endogenous’ subtypes of the disorder, respectively. Several lines of
research suggest that the biological underpinnings of ‘reactive’ or ‘endogenous’ subtypes may also differ, resulting
in differential response to treatment. We investigated this hypothesis by comparing the gene-expression profiles of
three animal models of ‘reactive’ and ‘endogenous’ depression. We then translated these findings to clinical samples
using a human post-mortem mRNA study.
Methods: Affymetrix mouse whole-genome oligonucleotide arrays were used to measure gene expression from
hippocampal tissues of 144 mice from the Genome-based Therapeutic Drugs for Depression (GENDEP) project. The
study used four inbred mouse strains and two depressogenic ‘stress’ protocols (maternal separation and
Unpredictable Chronic Mild Stress) to model ‘reactive’ depression. Stress-related mRNA differences in mouse were
compared with a parallel mRNA study using Flinders Sensitive and Resistant rat lines as a model of ‘endogenous’
depression. Convergent genes differentially expressed across the animal studies were used to inform candidate
gene selection in a human mRNA post-mortem case control study from the Stanley Brain Consortium.
Results: In the mouse ‘reactive’ model, the expression of 350 genes changed in response to early stresses and 370
in response to late stresses. A minimal genetic overlap (less than 8.8%) was detected in response to both stress
protocols, but 30% of these genes (21) were also differentially regulated in the ‘endogenous’ rat study. This overlap
is significantly greater than expected by chance. The VAMP-2 gene, differentially expressed across the rodent
studies, was also significantly altered in the human study after correcting for multiple testing.
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Conclusions: Our results suggest that ‘endogenous’ and ‘reactive’ subtypes of depression are associated with
largely distinct changes in gene-expression. However, they also suggest that the molecular signature of ‘reactive’
depression caused by early stressors differs considerably from that of ‘reactive’ depression caused by late stressors.
A small set of genes was consistently dysregulated across each paradigm and in post-mortem brain tissue of
depressed patients suggesting a final common pathway to the disorder. These genes included the VAMP-2 gene,
which has previously been associated with Axis-I disorders including MDD, bipolar depression, schizophrenia and
with antidepressant treatment response. We also discuss the implications of our findings for disease classification,
personalized medicine and case-control studies of MDD.
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Although antidepressants remain the first line treatment
for major depressive disorder (MDD), antidepressant
response varies considerably between individuals: fewer
than half of all patients achieve remission following
their first course of treatment [1]. The absence of robust
predictors of treatment response means that the most
effective antidepressant for a given patient is currently
identified by trial and error. This is often a long and costly
process which both delays recovery and has a negative
effect on long-term outcome [2].
Clinicians have long intuited that heterogeneity in
treatment response is the direct result of etiological hetero-
geneity in MDD [3]. Indeed, traditional diagnoses of major
depression proposed that the presence or absence of stress
prior to the onset of MDD results in two etiologically
distinct subgroups of the disorder with different treatment
recommendations. Early studies, which categorized these
subtypes as ‘reactive’ (occurring as the result of a stressor)
or ‘endogenous’ (occurring in the absence of stress), sug-
gested that those with ‘endogenous’ depression responded
more favorably to tricyclic antidepressants (TCAs) than se-
lective serotonin reuptake inhibitors (SSRIs) [4]. While the
validity of these subtypes remains unclear, reports continue
to show that both distal stress (occurring early in life [5])
and proximal stress (occurring near the onset of a depres-
sive episode [6]) are predictive of treatment response.
It remains unclear how the presence or absence of stress in
the etiology of MDD affects response to treatment. However,
it has been suggested that ‘endogenous’ and ‘reactive’ subtypes
of depression are associated with largely distinct biological
mechanisms, which respond differentially to treatment [3]. In
line with this hypothesis, a recent animal study reported that
the hippocampal gene-expression profile of a ‘reactive’ model
of depression (induced by chronic restraint stress) differed
considerably from that of an ‘endogenous’ model [7].
While this study suggests that the gene-expression
profiles of ‘reactive’ depression caused by proximal stress
may indeed differ from ‘endogenous’ depression, the role of
distal early-life stress in this distinction remains unknown.Several studies have highlighted the importance of the tim-
ing of adversity and show that early and late stressors may
have differential tissue-specific effects on gene-expression
in the hippocampus [8-12]. The pathophysiological pro-
cesses underlying MDD may therefore differ not only in
the presence or absence of a stressor, but also by the timing
of adversity (distal vs. proximal stress).
We investigated this hypothesis by exploring hippocam-
pal gene-expression (mRNA) differences in three ani-
mal models of depression chosen to represent ‘reactive’
and ‘endogenous’ depression. In the ‘reactive’ depres-
sion model, mice were exposed to either distal stress
(maternal separation) or proximal stress (unpredictable
chronic mild stress). Flinders sensitive rats, which show
congenital depression-like behavior, were used to model
‘endogenous’ depression.
Whole genome transcription profiles from disease rele-
vant brain tissues in animals may provide valuable support
and important information on the molecular mechanisms
that may be relevant in humans. Nevertheless, the specific
features of psychiatric illnesses means that molecular mech-
anisms uncovered in animal models are only suggestive and
need to be validated in human studies [13,14]. We therefore
used findings from the animal models to inform probe
set prioritization in a comparable human post-mortem
case-control study of depression from the Stanley Brain
Consortium. Specifically, we hypothesize that a set of genes
that shows concordant expression differences in response
to ‘reactive’ and ‘endogenous’ depression models in the
rodent studies may represent a common final pathway
to MDD. These same genes may therefore also be dif-
ferentially regulated in the post-mortem brain tissue of
humans with the disorder.
Methods
Design
Genome-wide expression profiling of the hippocam-
pus (HIP) from two studies from the rodent arm of
the Genome-based Therapeutic Drugs for Depression
(GENDEP) study [15] was used to inform candidate
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case-control study on MDD from the Stanley Brain
Consortium. The GENDEP project is a large-scale, multi-
center human pharmacogenomics study that also includes
a series of large-scale studies using animal models and
in vitro experiments. The GENDEP project was designed
to allow for integrative analysis of the results of the
transcriptomics and proteomics on the samples from
the human, the rodent and the in vitro studies, in order
to gain further insight into the molecular mechanisms
of MDD and identify biomarkers of antidepressant drugs
(AD) treatment response. The mouse study used 144 ani-
mals from four strains of well-characterized inbred mice
to model individual variation in humans. The mice were
subjected to one of two stress protocols and a control
condition (maternal separation (MS) - ‘early stress’, unpre-
dictable chronic mild stress (UCMS) - ‘late stress’ - or the
control condition (ENV)) to model ‘reactive’ depression.
Litters of each strain were randomly allocated to the MS,
UCMS or control group. Findings from the mouse study
were cross validated in a parallel rat study that compared
HIP mRNA differences between Flinders Sensitive and
Flinders Resistant rat lines as models of ‘endogenous’ de-
pression. Finally, genes differentially expressed in response
to both stress protocols in the mouse study and in the rat
study were used to inform probe set selection in compar-
able mRNA expression study in humans.
Animals
A total of 144 male and female mice (72 of each sex)
from four different strains ((129S1/SvImJ, C57LB/6 J,
DBA/2 J and FVB/NJ) were bred in the barrier unit at
the Institute of Psychiatry, London, UK. Weaning took
place when the animals were 21 to 28 days old. Animals
were group-housed under standard conditions with a
12:12 h light:dark cycle, 22°C ± 11°C, food and water ad
libitum. A total of 144 animals were sacrificed by cervical
dislocation. Animals used for the transcriptomic study were
not behaviorally tested. The hippocampus, liver and spleen
were dissected following previously published protocols
[16,17]. All housing and experimental procedures were car-
ried out in accordance with the UK Home Office Animals
(Scientific Procedures) Act, 1986.
A total of 39 animals from two cohorts of Flinders
Sensitive Lines and Flinders Resistant Lines (22 FRL and
17 FSL) were bred and maintained at Karolinska Institutet
(Stockholm) and housed under standard room temperature
(22 ± 1°C), relative humidity (45 to 55%) and a 12 h light:
dark schedule (light on at 07:00 a.m.). Food and water were
available ad libitum. The study was conducted as part of a
parallel GENDEP investigation. The Stockholm's Ethical
Committee for Protection of Animals approved the study
and all procedures were conducted in conformity with
the Karolinska Institutet's guidelines for the care anduse of laboratory animals, which follows the European
Communities Council Directive of 24 November 1986.
Additional information on the rat study is available
elsewhere [18].
UCMS (Unpredictable Chronic Mild Stress)
In mice, ‘reactive’ depression caused by proximal stress
was modeled using an Unpredictable Chronic Mild Stress
(UCMS) paradigm. A third of the 144 mice (48 male and
female mice) were exposed to varying stressors on a daily
basis for a period of two weeks. Exposure to UCMS com-
menced when the animals were 10 weeks of age. The
UCSM protocols included exposure to different stressors
each day in a pseudorandom order. The stressors in the
UCMS regime were based on previously published proto-
cols including two hours of home cage tilting at 45°, damp
bedding for four hours, cage switching for two hours,
flooded cage for 10 minutes, altered length and time of
light-dark cycle and air-puff [19]. Animals were exposed
to either one or two stressors each day for varying lengths
of time (Figure 1). All UCMS-exposed mice were tested
and maintained under standard laboratory conditions but
were single-housed. Following the UCMS regimen, a set
of animals was tested with a battery of behavioral tests in-
cluding Porsolt as an index of UCMS-evoked depressive-
behavior [19]. However, all animals used for this mRNA
characterization were not behaviorally tested to control
for the potential stressor effects of the tests.
MS (Maternal Separation)
A maternal separation protocol was used to model ‘reactive’
depression caused by distal stress in a further 48 mice. A
single 24-hour separation of the pup from the dam at post-
natal day (PND) 9 protocol was chosen to elicit a suffi-
ciently strong biological response. Day of birth was defined
as PND 0 for that particular litter. On postnatal Day 9 the
dam was removed from the litter for 24 hours. The litter
was kept on a heating pad in their home cage at 33°C ± 2°C
in a different room than the dam in order to avoid contact
through vocalization. Separated pups did not have access to
food or water during their separation period. Litters were
always separated and reunited with the mother during the
first half of the light phase. The first hour after reuniting
the litter with the mother was videotaped. Litters were of
different sizes and when possible each litter came from a
different breeding pair. A more detailed description of the
litters is published elsewhere [19].
‘Endogenous’ model of depression
Flinders Sensitive Lines (FSL) and Flinders Resistant Lines
(FRL) rats represent an ‘endogenous’ model of depression
[20-23]. Flinders Lines are strains originally obtained
by selective breeding of out-bred Sprague-Dawley rats
(SD), according to their resistance or sensitivity to
Figure 1 This figure shows the stress administration regime for the unpredictable chronic mild stress paradigm. The duration of the
stress regime was for two consecutive weeks and the order of the different stressors was randomized. This figure shows the stressors and time/
duration of administration for each of the two weeks.
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treatment [24]. FSL are congenitally more sensitive to
DFP and cholinergic agonists than FRL, which is a
neurobiological feature shared with depressed cases in
humans [21]. They also show many behavioral similarities
to human depressed patients, including decreased psycho-
motor activity and appetite, cholinergic hypersensitivity,
immune and sleep abnormalities including delay in rapid
eye movement (REM) sleep but preserved cognitive func-
tion and hedonic response [25]. Flinders rats remain a
robust model of depression to date [26].
mRNA extraction and lab protocols
Mouse brains, livers and spleens were dissected from
each animal and frozen on dry ice. Total RNA was
extracted from frozen hippocampal tissue and 3-ug
RNA was processed using the One Cycle Target Labelling
kit (Affymetrix, Santa Clara, CA, USA) and hybridized to
the mouse MOE430v2 Gene Expression Array (Affymetrix)
following standard Affymetrix protocols. Hippocampal
mRNA extraction from Flinders rats was performed by
another participating group from the GENDEP project
[18,22]. Briefly, cRNA probes were obtained and hybridized
to Affymetrix Rat Genome 230 2.0 using Affymetrix’s
One-Cycle Eukaryotic Target Labelling Assay protocol.
Protocols used for the human post-mortem mRNA ex-
traction are described in detail in the paper by Iwamoto
and colleagues [27]. Briefly, total RNA was extracted
from 0.1 g of frozen prefrontal cortex tissues using Trizol
(Invitrogen, Groningen, The Netherlands). A total of 8 to
10 mg of mRNA was reverse transcribed and synthesizedinto cDNA, hybridized onto Affymetrix HU95A oligo-
nucleotide arrays and scanned using an HP GeneArray
scanner (Hewlett-Packard, Palo Alto, CA, USA). Informa-
tion on The Stanley Foundation brain collection and
Neuropathology Consortium is found elsewhere [28].
Human samples
The human samples used in this study were donated to the
Stanley Foundation Brain Collection at the Department
of Psychiatry, University of the Health Sciences, Bethesda,
MD, USA and have been made available to researchers
world-wide. Human brain tissues were donated under stan-
dardized legislation according to the Uniform Anatomical
Gift Act (USA). Information on Stanley Medical Research
Institute (SMRI) and its research was offered to the next of
kin at the time of the donation. Additional information is
publically available from the Stanley Brain Consortium
website [29]. The primary transcription-wide analysis was
performed and described by Iwamoto and colleagues [27].
For consistency and quality assurance, the same subset
has been used without additions or subtractions of cases.
All data have been processed from raw files. The samples
used consist of post-mortem prefrontal cortex from the
Stanley Foundation Neuropathology Consortium from de-
ceased patients affected with major depressive disorder
and carefully matched controls. Exclusion criteria include
poor mRNA quality and age (>65). A total of 26 samples,
11 cases and 15 controls, were used congruent with the
primary data analysis (Table 1). Clinical diagnosis of MDD
was made following Diagnostic and Statistical Manual
of Mental Disorders – 4th Edition (DSM-IV) diagnostic
Table 1 Genes dysregulated by UCMS
Log 2 fold change
Transcript Gene name Pr. Rsum c57 DBA FVB 129 Pfp -Value
1418687_at Arc 2,841.834 -0.242 -0.279 -0.221 -0.127 <1.00E-04
1452453_a_at Camk2a 2,834.213 0.247 0.276 0.003 0.235 <1.00E-04
1427663_a_at Clk4 4,161.448 -0.420 -0.025 -0.196 -0.289 <1.00E-04
1436983_at Crebbp 1,498.852 0.600 0.156 0.176 0.566 <1.00E-04
1433733_a_at Cry1 5,285.620 0.438 0.113 0.070 0.238 <1.00E-04
1443805_at Dact3 4,920.751 -0.339 -0.097 -0.084 -0.292 <1.00E-04
1438892_at Dep1 3,046.244 0.157 0.142 0.164 0.571 <1.00E-04
1419580_at Dlg4 3,239.403 -0.224 -0.115 -0.177 -0.299 <1.00E-04
1453994_at Eml6 5,673.323 0.164 0.194 0.104 0.189 <1.00E-04
1430436_at Fam115a 4,086.744 0.425 0.025 0.069 0.434 <1.00E-04
1418240_at Gbp2 3,167.576 -0.183 -0.368 -0.335 -0.169 <1.00E-04
1417949_at Ilf2 4,243.511 -0.431 -0.112 -0.115 -0.279 <1.00E-04
1415899_at Junb 3,330.616 -0.246 -0.300 -0.349 -0.232 <1.00E-04
1457899_at Kalrn 4,503.738 0.238 0.169 0.088 0.408 <1.00E-04
1438403_s_at Malat1 1,725.168 -0.183 -0.464 -0.248 -0.139 <1.00E-04
1419568_at Mapk1 923.836 -0.704 -0.328 -0.203 -0.486 <1.00E-04
1420931_at Mapk8 2,498.977 -0.336 -0.180 -0.268 -0.193 <1.00E-04
1425459_at Mtmr2 4,168.453 -0.344 -0.198 -0.206 -0.236 <1.00E-04
1425014_at Nr2c2 3,897.542 0.420 0.016 0.169 0.421 <1.00E-04
1416505_at Nr4a1 4,665.395 -0.234 -0.148 -0.225 -0.161 <1.00E-04
1458176_at Per3 4,870.404 0.269 0.168 0.106 0.222 <1.00E-04
1416211_a_at Ptn 4,211.224 -0.439 -0.151 -0.176 -0.225 <1.00E-04
1440001_at Rian 4,837.821 0.284 0.070 0.192 0.279 <1.00E-04
1439940_at Slc1a2 2,581.498 0.547 0.079 0.059 0.441 <1.00E-04
1444489_at Slc25a12 4,744.455 0.293 0.077 0.117 0.197 <1.00E-04
1421924_at Slc2a3 3,356.425 -0.435 -0.125 -0.202 0.000 <1.00E-04
1421225_a_at Slc4a4 3,960.423 0.408 0.160 0.073 0.278 <1.00E-04
1455876_at Slc4a7 4,614.381 0.313 0.158 0.209 0.235 <1.00E-04
1457357_at Tlk2 3,989.909 0.288 0.100 0.059 0.395 <1.00E-04
Summary of genes found to be differentially expressed in response to the unpredictable chronic mild stress protocol and previously associated with stress
response. A stringent cut-off of P <1 × 10-04 and consistent directionality of fold change was used to identify differentially expressed across all four strains. The
table shows the probe set ID, Gene Name, Product Rank Sum (PR.Rsum) value, log 2 Fold change for each or the four strains and PFP value.
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psychiatrist. Additional information on the human sample
can be found in the Iwamoto and colleagues paper [27].
Statistical analysis of microarray data
Probe intensity data from 144 Affymetrix mouse whole-
genome oligonucleotide arrays (MOE 430 v2) were normal-
ized and summarized using the Robust Multichip Average
(RMA method) [30]. Probe sets that were systematically ab-
sent (based on the MAS 5.0 detection present/absent call)
across all the arrays were removed leaving 37,231 out of
the original 45,101 probe sets. A battery of quality control
metrics and exploratory analysis on the 144 arrays identified10 arrays that differed significantly in quality. These arrays
were removed for the purpose of the subsequent analysis;
further description on normalization methods is available
elsewhere [12,16].
In order to identify genes differentially expressed in
response to early and late stress protocols we performed
two sets of analyses. First, we compared normalized gene
expression measurements between maternally separated
animal (MS) and control (CON). Second, we compared
normalized gene expression measurements between UCMS
and CON. Differences were statistically evaluated using the
non-parametric algorithms implemented in the RankProd
package in the R environment [31,32]. RankProd enabled
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a meta-analysis approach with the RPadvance function.
This allowed us to circumvent issues arising from the
predominant strain effects by evaluating differences
within each strain first. Genes differentially expressed in
a single strain were analyzed using rank product (RP)
function from the same package, using the ‘data from
single origin’ option. The P-values were calculated with
1,000,000 permutations, and multiple testing was taken
into account by using the percentage of false prediction at
the very conservative threshold of PFP <0.001. A common
method to control for the number of rejected hypothesis
in ‘omics’ study is to compute and report the false discov-
ery rate (FDR) as proposed by Benjamini and Hochberg.
The RankProd package returns proportion of false positive
(PFP), which is a method proposed by Fernando and
colleagues. Contrary to FDR, PFP does not rely on the
correlation between tests and the number of tests per-
formed [33]. Although PFP and FDR are often equated,
the two methods differ in that PFP controls the proportion
of accumulated false positives while FDR controls the
expected proportion of false positive. FDR is not the
best method to use in cases where there is a relation-
ship between variables, which in mRNA studies is gen-
erally driven by genetic regulatory pathways and cross
hybridization. We therefore corrected using the PFP
method across all studies where we use the RankProd
algorithim. The genes significantly altered were identified
by the PANTHER classification system [34]. Genes with
PFP <0.001 were subsequently uploaded to the Ingenuity
database for pathway analysis with the Ingenuity Pathway
Analysis (IPA) software (QIAGEN’s Ingenuity® Pathway
Analysis (IPA®, Redwood City, USA) [35].
Expression data from FSL and FRL animals have
been made available on the Gene Expression Omnibus
(GEO; accession number GS2088, [36]. Data have been
processed from raw. CEL files to ensure consistency of
data analysis across all animal studies. To control for
potential batch effects we combined the rat datasets
from two cohorts using the ComBat function built into
the inSilicoMerging package for the R environment
[37]. Probe sets were normalized and summarized using
Robust Multichip Average (RMA method). Probe sets that
were systematically absent (based on the MAS 5.0 absent/
present detection call) were removed. Probe-set sum-
maries from FSL and FRL were then compared using
the RankProd non-parametric algorithm implemented in
R using the PRadvance function and single origin option.
P-values were evaluated using 1,000,000 permutations.
A conservative false discovery rate (PFP) threshold of
P <0.001 and a change fold >1.5 was used. Probe sets
that met the statistical thresholds were subsequently
annotated using PANTHER [34] to obtain a list of gene
symbols. We then matched all genes differentially expressedacross all rodent studies using scripts written in Python
[38]. Convergent genes differentially expressed across
all rodent studies were subsequently analyzed using IPA
software. Lastly, all genes differentially expressed in
response to both “reactive” and “endogenous” models
of depression were used to inform probe set selection
in the human study.
Raw scores from 26 Affymetrix human oligonucleotide
arrays (HU95A) were normalized and summarized into
probe sets using the RMA method, which returned log2
transformed intensities [30]. Intensity distributions, profile
correlations and quality control metrics were applied. MAS
5.0 expression values were calculated based on scaling
to a target intensity of 100, then transformed by Log2
and calls were computed using the MAS5.0 present/
absent algorithm. Affymetrix HU95A incorporates over
12,000 probe sets, tagging the expression of over 5,000
well-characterized genes. Human genes, ortholog to genes
differentially expressed across all three rodent studies, were
obtained using the Mouse Genome Informatics orthology
query [39]. The Affymetrix Netaffx tool [40] was used to
identify probe sets on the HU95A chip (Affymetrix) tagging
the expression of the human genes. Expression differences
between human MDD cases and controls were evaluated
using the RankProd non-parametric algorithm imple-
mented in R using the single origin function. Candidate
genes in humans informed by the results from the mouse
study were considered differentially expressed at a stringent
corrected significance threshold PFP <0.05 using permuta-
tion testing with 1,000,000 permutations.
Results
Gene expression profiles in ‘reactive’ depression models
The Rankprod method was used to identify the most
robustly differentially expressed genes between ‘late’
(UCMS) stressed animals and control and between ‘early’
(MS) stressed animals and control. We considered only
those genes that show consistency in the direction of
change across all four strains. Inconsistency in the direction
of change indicates Stress x Strain interaction effects, which
are not specific to our research question. The results of this
analysis uncovered 406 probe sets altered in response to
UCMS across all four strains. These probes tag the expres-
sion of 370 known genes in mice. A summary of genes un-
covered from this analysis with a previous association with
stress response or MDD is presented in Table 1. The results
reveal a number of genes previously associated with UCMS
protocols and believed to play a role in the pathogenesis of
MDD. The same analysis was repeated to compare the ma-
ternally separated animal (MS) and control. The results
from this analysis revealed 396 probe sets differentially reg-
ulated in response to the maternal separation protocol.
These probe sets could be mapped to 350 known genes in
mice. A summary of the top genes differentially expressed
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in Table 2. We then explored the number of altered genes
in response to either ‘early’ or ‘late’ stressors as well as the
genetic overlap between the two conditions (Figure 2).
There were remarkably few. Only 67 genes, less than 8.8%
of significantly altered genes were in common between
mice exposed to early and late stress paradigms.
The minimal gene expression overlap suggests that the
biological mechanisms underpinning ‘reactive’ depression
caused by early and late stressors differs considerably. In
order to gain further understanding into these differences,
genes differentially expressed for each of the two models
were analyzed using IPA [35]. This allowed us to uncover
gene networks showing the molecular relationship betweenTable 2 Genes dysregulated by MS
Transcript Gene Name Pr. Rsum c57
1454655_at Dgkd 3,024.390 0.276
1450392_at Abca1 3,716.966 0.014
1416250_at Btg2 2,390.318 -0.346
1416332_at Cirbp 3,963.875 -0.301
1427663_a_at Clk4 3,977.651 -0.349
1458518_at Cpeb2 2,642.230 -0.336
1451977_at Dyrk1a 4,954.256 -0.133
1421142_s_at Foxp1 3,977.517 -0.369
1439717_at Gabrg3 5,191.066 -0.174
1422223_at Grin2b 4,777.728 -0.220
1438441_at Id4 3,829.228 0.313
1420931_at Mapk8 2,623.666 -0.158
1425459_at Mtmr2 4,660.997 -0.283
1437660_at Nktr 5,633.677 -0.089
1443970_at Ntrk3 3,929.819 0.261
1437213_at Nudt21 4,091.995 0.234
1453750_x_at Pitpnc1 5,481.080 -0.305
1418015_at Pum2 3,066.939 -0.032
1428462_at Ppp2r5e 5,555.808 -0.212
1428905_at Rraga 2,709.505 -0.266
1421346_a_at Slc6a6 2,560.666 -0.421
1420867_at Tmed2 2,172.246 -0.329
1435770_at Tmx4 4,098.309 -0.197
1459737_s_at Ttr 1,229.204 0.678
1420833_at Vamp2 3,820.922 -0.133
1450308_a_at Xrn1 2,743.074 -0.175
1420816_at Ywhag 1,838.774 -0.265
1448219_a_at Ywhaz 3,773.496 -0.314
Summary of genes found to be differentially expressed in response to the materna
directionality of fold change was used to identify differentially expressed across all
(PR.Rsum) value, log2 Fold change for each or the four strains and PFP value.the genes and evaluate networks according to the fit of
significant genes in each dataset [12]. First, we explored
gene networks associated with ‘late’ UCMS protocols. A
total of 350 genes from our reference list were found on
the IPA database. The top two functional networks identi-
fied by IPA have a score >42, with 29 reference molecules
included in the first network and 23 in the second. Both
networks were significantly associated with stress signaling
response. The most significant transcriptional regulators
included ELK1/2/4 TFIIA, SMARCB, CREB1 and THRB
(see Additional file 1: Figure S1 and Additional file 2:
Figure S2). We repeated the pathway analysis with genes
differentially expressed in response to ‘early’ (MS) stressors.
A total of 347 genes from our reference list were found onLog 2 Fold Change
DBA FVB 129 Pfp -Value
0.399 0.147 0.273 <1.00E-04
0.208 0.150 0.319 <1.00E-04
-0.301 -0.161 -0.500 <1.00E-04
-0.086 -0.237 -0.335 <1.00E-04
-0.215 -0.271 -0.127 <1.00E-04
-0.401 -0.247 -0.177 <1.00E-04
-0.206 -0.235 -0.168 <1.00E-04
-0.264 -0.153 -0.143 <1.00E-04
-0.254 -0.169 -0.021 <1.00E-04
-0.129 -0.225 -0.223 <1.00E-04
0.324 0.290 0.046 <1.00E-04
-0.373 -0.164 -0.333 <1.00E-04
-0.212 -0.165 -0.169 <1.00E-04
-0.008 -0.178 -0.226 <1.00E-04
0.388 0.117 0.254 <1.00E-04
0.294 0.040 0.018 <1.00E-04
-0.146 -0.065 -0.179 <1.00E-04
-0.362 -0.146 -0.438 <1.00E-04
-0.192 -0.085 -0.273 <1.00E-04
-0.447 -0.169 -0.322 <1.00E-04
-0.418 -0.238 -0.333 <1.00E-04
-0.291 -0.457 -0.250 <1.00E-04
-0.078 -0.313 -0.140 <1.00E-04
0.186 0.074 0.376 <1.00E-04
-0.172 -0.256 -0.244 <1.00E-04
-0.373 -0.340 -0.306 <1.00E-04
-0.294 -0.419 -0.362 <1.00E-04
-0.283 -0.323 -0.252 <1.00E-04
l separation stress protocol. A stringent cut-off of P <1 × 10-04 and consistent
four strains. The table shows the probe set ID, Gene Name, Product Rank Sum
Figure 2 Venn diagram showing the number of genes
significantly altered in response each depressogenic protocol.
A compelling finding is the limited number of overlapping genes
(approximately 8.8%) suggesting that etiologically different
molecular mechanisms underpin a congruent set of behaviors.
Figure 3 Venn diagram showing the number of genes
overlapping across all rodent studies. Only 67 genes were
differentially regulated in response to both early (MS) and late
stressors (UCMS) pointing at minimal genetic overlap. However,
many of these genes (approximately 30%) were also differentially
regulated in an endogenous rat model of depression. The
replication of these genes in a different organism that shows
congenital depression-like symptoms, points at molecular
mechanisms that may be involved in the human pathology.
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http://www.biomedcentral.com/1741-7015/12/73the IPA knowledge database. IPA returned three net-
works with a score >40. The associated functions of the
top networks include mRNA post-transcriptional modi-
fication, protein synthesis and cellular development.
The networks are associated with developmental and
neurological disorders, which is a good match to the
“early” stress protocol used. The top-ranking network
(see Additional file 3: Figure S3) includes 29 focus mole-
cules from our reference gene set. The most prominent
interacting genes within this network are with the
Yhwaz and Yhwag. These genes are of particular interest
as they have been systematically uncovered across sev-
eral proteomic and transcriptomic studies from the
GENDEP project in both mice and rats [12,13,17,22].
These genes show a direct interaction with the STK25
kinase, which plays a role in stress response. The second
network (Additional file 4: Figure S4) is composed of
27 molecules from our reference dataset. This network
is centered on the NF-κB complex. The nuclear factor-
κB (NF-κB) is a ubiquitous transcription factor involved
in the regulation of gene expression and cell stress re-
sponse and cell proliferation. Interestingly, NF-κB can
be activated by different stimuli, including cytokines
(such as TNF-α and IL-1): this finding is congruent with
the inflammation hypothesis for MDD [41-45].
Gene expression profiles in ‘endogenous’ depression models
To gain an understanding of the similarities between stress-
induced ‘reactive’ depression and a congenital ‘endogenous’
model of depression, we compared genes differentially
regulated in response to early (MS) and late stress (UCMS)
with mRNA differences between Flinders sensitive and
resistant lines. Flinders lines are a genetic animal model ofdepression that allows us to cross-validate stress-altered
genes within a parallel, independent mRNA study where
depressive-behaviors occur in the absence of environmental
stressors. The RankProd algorithm and conservative
cut-offs described previously was used to evaluated
mRNA differences between Flinders Sensitive and Flinders
Resistant lines. The results revealed 715 down-regulated
and 1,145 up-regulated probe sets. To obtain a list of gene
names, probe sets obtained were subsequently anno-
tated using PANTHER [34]. The probe sets tagged the
expression of 501 down-regulated and 727 up-regulated
genes. A total of 1,228 genes were used for cross-validation
with the mouse study. First, we explored the genomic
overlap between maternally deprived animals and Flinders
line rats. From a total of 350 genes differentially regu-
lated in maternally deprived mice, a total of 65 genes
(19%) were also differentially regulated in rats. The same
comparison was performed with genes differentially
expressed in mice exposed to UCMS. A total of 52
genes (11%) were differentially expressed between ‘late’
stress animals and Flinders rats. A compelling finding
is that 21 genes are differentially expressed in rats and
in both early and late stressed mice (Figure 3). This is
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were commonly expressed between early and late
stressed animals in the first place. Validations in an
independent, methodologically different study using a
genetic model of depression point to an important
genetic overlap between stress-related and syndrome-
related mechanisms. In order to gain further biological
insight, genes significantly altered in response to both
stresses in mice and between Flinders Sensitive and
Resistant lines were carried forward for analysis using
Ingenuity’s IPA system. All 21 genes were found in the
Ingenuity reference database. A significant network
with a score >40 consisting of over 55% of the refer-
ence molecules (12/21) was revealed (Figure 4). Among
the genes in the pathway, four genes (Ywhaz, Ppm1a,
Nkfb and Mapk1) are of particular interest as they haveFigure 4 Network analysis performed on converging genes differenti
between different selected Flinders lines. The pathway comprises over
system (12 out of the 21 reference molecules). The pathway implicates a n
treatment response, including Ppm1a, Ywhaz, NkFb and Mapk.been previously reported across different “omics” GENDEP
investigations [12,17,46-48].
Translating findings to humans
From a total of 21 genes differentially expressed across all
three rodent studies, 15 human orthologs were found.
The expression of these 15 genes is tagged by 21 probe
sets on the Affymetrix HU95A oligonucleotide array.
The RankProd algorithm was used to evaluate expression
between post-mortem cases and controls. Out of a total of
15 genes, the VAMP-2 is significantly down-regulated after
correcting for the number of multiple non-independent
tests using a prediction of false discovery rate of PFP <0.05
(Table 3). In our study, the Vesicle-Associated Membrane
Protein 2 (VAMP-2: Synaptobrevin2) gene is significantly
altered across all rodent studies and in the human study.ally regulated in response to different stresses in mouse and
half the reference molecules uploaded to the Ingenuity database
umber of genes previously associated with MDD and antidepressant
Table 3 Convergent genes across all rodent studies
Probe Set ID Gene symbol RP/Rsum PFP P-value
1034_at TIMP3 10.3564 1.0512 0.6398
1035_g_at TIMP3 10.788 0.9069 0.7097
1235_at YWHAZ 8.1361 1.8677 0.2436
2018_at GJA1 10.6102 0.9224 0.6818
296_at TUBB2A 8.1718 1.4332 0.2493
297_g_at TUBB2A 10.38 0.9872 0.6438
32254_at VAMP2 9.7002 0.0024 0.5228
32531_at GJA1 5.6354 0.4128 0.018
32572_at USP9X 9.6037 1.0556 0.5049
32761_at SRRM2 11.6727 0.9074 0.8285
34387_at LPGAT1 10.5963 0.9769 0.6796
34642_at YWHAZ 6.7492 0.8804 0.0766
36307_at ARC 8.5526 1.0273 0.3127
36760_at YWHAZ 9.8422 0.9712 0.5489
38211_at ZBTB20 8.6008 0.8204 0.321
38710_at OTUB1 9.566 1.145 0.4978
39331_at TUBB2A 8.2579 1.2097 0.263
39725_at RBM39 10.946 0.888 0.7336
40096_at ATP5A1 8.5727 0.9088 0.3161
40125_at CANX 8.2587 1.0086 0.2631
968_i_at USP9X 11.0827 0.8662 0.7532
The expression profile of these genes is tagged by 21 probe sets. Expression
differences between cases and control were evaluated using the RankProd
algorithm using probability of false positive (PFP) of less the 0.05 to control for
the number of multiple testing. The table shows Probe Set ID, Gene Symbol,
RankProd value, corrected PFP value and uncorrected -value. The only gene
that survives correction for multiple testing in the human analysis is the
VAMP-2 gene.
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The main objective of this study was to compare the
genomic signatures of ‘reactive’ and ‘endogenous’ models
of depression in three rodent studies and translate these
findings in a human study. We found that all three animal
models of depression had largely unique gene-expression
profiles indicating divergent molecular mechanisms. Never-
theless, a small set of genes was consistently dysregulated
across each paradigm and in the post-mortem brain tissue
of depressed patients, which may represent a final common
pathway to the disorder.
Gene-expression profiles of ‘endogenous’ and ‘reactive’
models of depression
Consistent with our hypothesis and with previous findings,
the gene-expression profiles of both of our ‘reactive’ models
of depression were largely distinct from our ‘endogenous’
model. Interestingly, this differed according to which
‘reactive’ depression paradigm was compared. For the
early or stress ‘reactive’ model 19% of genes overlapped withthe endogenous model, while for the late stress ‘reactive’
model the overlap was considerably lower at just 11%.
Surprisingly, the genomic signatures of our two ‘reactive’
models were more distinct from one another than the
‘endogenous’ model with fewer than 9% of genes shared
between the two paradigms. This suggests that the two
different models result in depressive-like behavior in
mice through distinct biological mechanisms. Interestingly,
gene pathway analysis returned plausible functional
networks, with the more significant network for ‘early’
stressed animals associated with neurodevelopmental
disorders and those of ‘late’ stressed animals associated with
cell stress response and cell-signaling. Taken together, our
results suggest that early exposure to stress modulates
the expression of genes belonging to pathways associated
with neurodevelopmental mechanisms. These changes may
condition an individual’s exposure to later stresses and
response to pharmacological and behavioral interven-
tions later in life in yet unclear ways. Conversely, late
onset stresses may act primarily on brain neurochemistry
with neurostructural changes occurring via the cascading
effects of neurochemically-related mechanisms, including
neurogenesis and apoptosis [49].
Genes differentially regulated across all three paradigms
While each of our three animal models of depression
showed largely distinct gene-expression profiles, a set of
genes were differentially regulated across all three para-
digms. Pathway analysis of these genes revealed a gene
network which included Ppm1a, Ywhaz, Nkfb and Mapk.
All four genes have each been implicated in both the
etiology of MDD and the response to treatment and may,
therefore, represent a final common pathway to the
disorder. We previously reported that the expression
ppm1a was significantly modulated by the antidepressant
nortriptyline. We have also shown that several single
nucleotide polymorphisms in the human ortholog of
this gene (PPM1A) predict a response to the same drug
in a parallel human pharmacogenetic study [46]. Tyrosine
3-monooxygenase/tryptophan 5-monooxygenase activation
protein (Ywhaz) has systematically been uncovered across
several GENDEP studies and plays a role in cell prolifer-
ation and neurogenesis, which is a current explanatory
model of MDD [50-54]. Moreover, it interacts with IRS1
protein and the MAPK pathway by modulating the acti-
vation of JNK1 and p38 MAPK both of which have been
systematically associated with depressive mechanisms
[52-56]. Lastly, the Nfkb gene has extensively been asso-
ciated with peripheral inflammation and is consistent
with the inflammation hypothesis for MDD [57].
Convergent animal-human genes
Animal models are an attractive proposition for the study
of mood disorders as they allow access to disease relevant
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However, given the nature and characteristic of psychiatric
disorders, there are aspects of these illnesses that can only
be studied in humans. We therefore attempted to translate
our set of convergent genes emerging from the rodent
studies in a matching human post-mortem mRNA study
of depressed cases and controls. One gene, the VAMP-2
gene, remained significantly down-regulated after correct-
ing for multiple testing in the human study. The vesicle-
associated membrane protein (VAMP-2; synaptobrevin2)
plays a role in the molecular regulation of transmitter re-
lease at the presynaptic plasma membrane. The expression
of VAMP-2 has been found to be altered in both schizo-
phrenia and bipolar disorder within a combined microarray
analysis of the Stanley Foundation's brain collections [58].
Moreover, several other studies have implicated this gene in
Axis-I psychiatric disorders and in antidepressant treatment
response [59-62]. Previous studies have also shown that the
VAMP2/synaptobrevin-2 gene is increased in rat frontal
cortex after chronic antidepressant treatment and repeated
electro-convulsive therapy (ECT), although the finding has
not been consistently replicated [63,64].
Implications
If replicated, the results of our study may have far reaching
implications for both personalized medicine for MDD and
case-control studies of the disorder.
Our findings suggest that etiological factors (such as
proximal and distal stressors) could be used to indicate
the molecular mechanisms at work in a given patient
and, therefore, select the most effective treatment. Indeed,
several studies have shown that proximal and distal stress
predicts a response to antidepressants. Interestingly, while
proximal stressors, such as divorce or job loss, have
been linked with a good response [3], distal stressors,
such as childhood maltreatment, are associated with a
less favorable outcome [5]. Our results suggest that
these contradictory findings may be explained by the
divergent molecular mechanisms underlying ‘reactive’
depression caused by early versus late stressors. Neverthe-
less, further studies in clinical samples would be required
to test this hypothesis.
Heterogeneity in the molecular mechanisms under-
lying depression could explain why, despite considerable
efforts, genome-wide association studies (GWAS) of
depression have yet to identify statistically significant
associations with MDD [65]. This same heterogeneity
may also explain the paucity of findings from pharmaco-
genetic studies of MDD, including the very large GWAS,
NEWMEDS [66]. If the molecular mechanisms under-
lying MDD differ according to stress, it is plausible that
different genetic variants would predict response to
treatment in stressed and non-stressed individuals. In
line with this, several studies have shown that geneticvariants and stress have interdependent effects on anti-
depressant response [67].
While our findings highlight the heterogeneity of de-
pression, they also suggest that a small set of genes may
be involved in a final common pathway to the disorder.
Replication of these findings in further transcriptomic
studies of clinical samples is necessary before any firm
conclusions can be drawn about the role of these genes
in MDD. However, if they are successful, the existence
of a final common pathway provides an exciting pro-
spect for the development of novel antidepressants. If
indeed the heterogeneity of MDD explains inter-individual
variation in treatment response, it is plausible that an-
tidepressants, which target this final common pathway,
may prove to be effective for all patients, regardless of
their etiological factors.
Limitations
Our findings should be considered in the context of several
important limitations.
First, we used whole genome gene-expression data from
four different samples in our study. While this approach
allowed us to conduct integrative analyses across species
and translate our findings from rodents to humans, it also
meant that our analyses were subject to multiple testings.
We used stringent thresholds both within and across ana-
lyses in order to protect against the risk of false positive
findings. Nevertheless, in taking such an approach it is pos-
sible that we inflated the number of false negatives. Further
replication of our results in larger independent samples is
therefore necessary to confirm our findings.
Second, our rodent models focused exclusively on gene-
expression in the hippocampus and did not include further
brain structures implicated in the neurobiology of MDD,
such as the amygdala. Moreover, limited public human de-
pression hippocampal transcript array data were available
at the time of analysis which meant that our human study
used gene-expression data collected from a different, but
still disease relevant, brain region (the prefrontal cortex). It
is plausible, therefore, that the use of a different brain re-
gion resulted in false negatives in the human component of
our study. Our findings, therefore, require confirmation in
further brain regions in both animal and human samples.
Finally, it is important to note that rodents do not
capture the complex characteristics of psychiatric ill-
nesses that can only be fully investigated in human
studies. Nevertheless, there are many advantages of
animal models, which allow access to disease relevant
brain tissues and control of environmental conditions.
In the current study, we attempted to capture the full
potential of both animal and human studies by con-
ducting integrative analyses using several independent
animal studies and translating results in a disease-relevant
but different brain region in humans.
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It is largely accepted that there are multiple causal pathways
to MDD consisting of different combinations of genetic
and environmental risk factors [67]. However, it remains
unclear whether these factors converge on a unitary mo-
lecular mechanism underlying MDD or MDD consists of a
heterogeneous group of disorders with multiple causal fac-
tors and distinct molecular mechanisms. Our findings pro-
vide support for both of these hypotheses. Using an animal
model, we have shown that the presence and timing of
stress determines distinct molecular processes underlying
depressive behavior. However, we also identified a small set
of genes which were consistently dysregulated across each
stress paradigm and in post-mortem brain tissue of de-
pressed patients suggestive of a final common pathway to
the disorder. These genes included VAMP-2, a gene which
has previously been associated with Axis-I disorders includ-
ing MDD, bipolar depression, schizophrenia and with anti-
depressant treatment response.
Careful consideration of the etiological pathways to
MDD may be key to dissecting the heterogeneity of the
disorder and understanding and predicting response to
treatment. Nevertheless, a final common pathway which
unites the disparate etiologies of MDD may yet provide
a target for novel treatments which are effective for all,
rather than just subsets of patients.Additional files
Additional file 1: Figure S1. Gene network obtained from genes
differentially expressed in response to the UCMS protocol. The most
significant network returned from the Ingenuity Pathway Analysis
software for genes differentially expressed in response to Unpredictable
Chronic Mild Stress. The network consists of 29 reference molecules and
is significantly associated with cell stress response.
Additional file 2: Figure S2. Second gene network obtained from
genes differentially expressed in response to the UCMS protocol. A
second significant network with a score >42 returned by the Ingenuity
Pathway Analysis software for genes differentially expressed in the mouse
study in response to the Unpredictable Chronic Mild Stress protocol. The
pathway includes 23 reference molecules and it is also associated with
cell stress response. The pathway is centered on the ELK complex hub
and is of particular interest as it shows the VAMP-2 complex and its
association with the N-type calcium channel and potassium channel.
Additional file 3: Figure S3. Gene network obtained from genes
differentially expressed in response to the Maternal Separation protocol.
The most significant network returned from the Ingenuity Pathway
Analysis software for genes differentially expressed in response to the
maternal separation depressogenic protocol. Of particular interest is the
presence of the Yhwaz reference molecule. The Yhwaz gene has been
systematically uncovered across several animal studies and been shown
to influence neurotransmission of dopamine by regulating exocytosis or
phosphorylation of synaptic proteins. The pathway consists of 29
reference molecules and is associated with cell stress response.
Additional file 4: Figure S4. Second Gene network obtained from
genes differentially expressed in response to the Maternal Separation
protocol. Second pathway returned from the Ingenuity Pathway Analysis
software for genes differentially expressed in response to the maternal
separation protocol in mouse. This pathway includes 27 reference
molecules and is centered on the NF-κB hub. The pathway is associatedwith cell proliferation and the NF-κB hub has been previously found to
be associated with inflammation. Activation of the NF-κB transcription
family, by nuclear translocation of cytoplasmic complexes, plays a central
role in inflammation [68]. Human studies have shown that MDD patients
with increased early life stress exhibit enhanced inflammatory responsiveness
to psychosocial stress [69].
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